CN100346782C - 一种含氨基酸的维生素c组合物 - Google Patents
一种含氨基酸的维生素c组合物 Download PDFInfo
- Publication number
- CN100346782C CN100346782C CNB2004100425493A CN200410042549A CN100346782C CN 100346782 C CN100346782 C CN 100346782C CN B2004100425493 A CNB2004100425493 A CN B2004100425493A CN 200410042549 A CN200410042549 A CN 200410042549A CN 100346782 C CN100346782 C CN 100346782C
- Authority
- CN
- China
- Prior art keywords
- vitamin
- powder injection
- injectable sterile
- sterile powder
- injection composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 211
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims abstract description 100
- 229930003268 Vitamin C Natural products 0.000 title claims abstract description 100
- 235000019154 vitamin C Nutrition 0.000 title claims abstract description 100
- 239000011718 vitamin C Substances 0.000 title claims abstract description 100
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims description 50
- 238000002347 injection Methods 0.000 claims abstract description 41
- 239000007924 injection Substances 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 41
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 31
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 27
- 229940024606 amino acid Drugs 0.000 claims description 27
- 235000001014 amino acid Nutrition 0.000 claims description 27
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 25
- 239000004472 Lysine Substances 0.000 claims description 16
- 229960002885 histidine Drugs 0.000 claims description 14
- 235000019766 L-Lysine Nutrition 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 235000014304 histidine Nutrition 0.000 claims description 3
- 235000018977 lysine Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000007788 liquid Substances 0.000 description 30
- 238000012856 packing Methods 0.000 description 30
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 19
- 239000000284 extract Substances 0.000 description 19
- 239000007789 gas Substances 0.000 description 18
- 239000002131 composite material Substances 0.000 description 17
- 229910052782 aluminium Inorganic materials 0.000 description 15
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OGDDUPYYEQZVHV-KDDYFZQKSA-N (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N OGDDUPYYEQZVHV-KDDYFZQKSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
样品 | 各组分重量比 | 溶液pH值 | 产气量(ml) | |||
维生素C | L-精氨酸 | L-赖氨酸 | L-组氨酸 | |||
市售样品 | 1g维生素C、0.25g无水碳酸钠 | 4.82 | 51.9 | |||
实施例1 | 50 | 50 | 0 | 0 | 6.86 | 0 |
实施例2 | 52.2 | 47.8 | 0 | 0 | 5.23 | 0 |
实施例3 | 58.8 | 41.2 | 0 | 0 | 4.51 | 0 |
实施例4 | 65.3 | 34.7 | 0 | 0 | 4.16 | 0 |
实施例5 | 50 | 0 | 50 | 0 | 5.58 | 0 |
实施例6 | 50.8 | 0 | 49.2 | 0 | 5.29 | 0 |
实施例7 | 51.8 | 0 | 48.2 | 0 | 5.09 | 0 |
实施例8 | 54.2 | 0 | 45.8 | 0 | 4.77 | 0 |
实施例9 | 61.1 | 0 | 38.9 | 0 | 4.35 | 0 |
实施例10 | 66.7 | 0 | 33.1 | 0 | 4.09 | 0 |
实施例11 | 40.3 | 0 | 0 | 59.7 | 5.97 | 0 |
实施例12 | 50 | 0 | 0 | 50 | 5.41 | 0 |
实施例13 | 60 | 0 | 0 | 40 | 4.48 | 0 |
实施例14 | 66.7 | 0 | 0 | 33.3 | 4.12 | 0 |
样品 | 抽取药液操作方便性比较 |
市售样品 | 溶解时压力过大,有气体从针口处排出。待气体不排出后抽取药液,进针时注射器活塞突然受到压力难以把持,拔出针头时药液在反作用力作用下容易喷出。 |
实施例1 | 普通方式抽取药液,方便 |
实施例2 | 普通方式抽取药液,方便 |
实施例3 | 普通方式抽取药液,方便 |
实施例4 | 普通方式抽取药液,方便 |
实施例5 | 普通方式抽取药液,方便 |
实施例6 | 普通方式抽取药液,方便 |
实施例7 | 普通方式抽取药液,方便 |
实施例8 | 普通方式抽取药液,方便 |
实施例9 | 普通方式抽取药液,方便 |
实施例10 | 普通方式抽取药液,方便 |
实施例11 | 普通方式抽取药液,方便 |
实施例12 | 普通方式抽取药液,方便 |
实施例13 | 普通方式抽取药液,方便 |
实施例14 | 普通方式抽取药液,方便 |
样品 | 吸收度(420nm) | ||
0天样品 | 5天样品 | 10天样品 | |
市售样品 | 0.015 | 0.017 | 0.020 |
实施例1 | 0.020 | 0.024 | 0.027 |
实施例12 | 0.022 | 0.022 | 0.024 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100425493A CN100346782C (zh) | 2004-05-21 | 2004-05-21 | 一种含氨基酸的维生素c组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100425493A CN100346782C (zh) | 2004-05-21 | 2004-05-21 | 一种含氨基酸的维生素c组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1698600A CN1698600A (zh) | 2005-11-23 |
CN100346782C true CN100346782C (zh) | 2007-11-07 |
Family
ID=35474953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100425493A Expired - Lifetime CN100346782C (zh) | 2004-05-21 | 2004-05-21 | 一种含氨基酸的维生素c组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100346782C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1299676C (zh) * | 2005-03-15 | 2007-02-14 | 中国人民解放军第三军医大学 | 一种抗缺氧药物组合物 |
CN104610202B (zh) * | 2015-01-30 | 2017-03-08 | 精晶药业股份有限公司 | 一种维生素c‑精氨酸的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3178451A (en) * | 1962-03-14 | 1965-04-13 | R P Howard & Company | Vitamin c compositions and method of producing same |
GB1125675A (en) * | 1966-02-10 | 1968-08-28 | Kyowa Hakko Kogyo Kk | Stable ascorbic acid composition and process for preparing the same |
CN1074371A (zh) * | 1993-01-19 | 1993-07-21 | 王景文 | 抗坏血酸止血粉 |
WO2003018000A1 (en) * | 2001-08-24 | 2003-03-06 | Rath Matthias M D | Novel ascorbic acid compounds, methods of synthesis and application |
-
2004
- 2004-05-21 CN CNB2004100425493A patent/CN100346782C/zh not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3178451A (en) * | 1962-03-14 | 1965-04-13 | R P Howard & Company | Vitamin c compositions and method of producing same |
GB1125675A (en) * | 1966-02-10 | 1968-08-28 | Kyowa Hakko Kogyo Kk | Stable ascorbic acid composition and process for preparing the same |
CN1074371A (zh) * | 1993-01-19 | 1993-07-21 | 王景文 | 抗坏血酸止血粉 |
WO2003018000A1 (en) * | 2001-08-24 | 2003-03-06 | Rath Matthias M D | Novel ascorbic acid compounds, methods of synthesis and application |
US20030119753A1 (en) * | 2001-08-24 | 2003-06-26 | Roomi Waheed M. | Novel ascorbic acid compounds, methods of synthesis and application use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1698600A (zh) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1623543A (zh) | 依普西龙组合物 | |
CN100586422C (zh) | 比伐卢定冻干粉针剂及其制备方法 | |
AU768169B2 (en) | Pharmaceutically stable oxaliplatinum preparation for parenteral administration | |
KR101468153B1 (ko) | 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법 | |
CN112402371B (zh) | 一种瑞德西韦注射液及其制备方法 | |
CN100346782C (zh) | 一种含氨基酸的维生素c组合物 | |
CN101623255B (zh) | 一种青蒿琥酯纳米乳药物组合物及其制备方法 | |
JP5070670B2 (ja) | N−[o−(p−ピバロイルオキシベンゼンスルホニルアミノ)ベンゾイル]グリシン・モノナトリウム塩・4水和物の凍結乾燥製剤およびその製造方法 | |
CN101053557A (zh) | 重酒石酸去甲肾上腺素药物组合物冻干粉针注射剂 | |
RU2272623C2 (ru) | РАСТВОР ТЕТРАГИДРАТА МОНОНАТРИЕВОЙ СОЛИ N-[O-(п-ПИВАЛОИЛОКСИБЕНЗОЛСУЛЬФОНИЛАМИНО)БЕНЗОИЛ]ГЛИЦИНА И ГОТОВАЯ ЛЕКАРСТВЕННАЯ ФОРМА НА ЕГО ОСНОВЕ | |
CN1689564A (zh) | 一种含维生素c钠的维生素c组合物 | |
CN1762341A (zh) | 治疗心脑血管疾病、肝脏疾病的丹参酚酸复合物及其应用 | |
CN1698820A (zh) | 一种退黄保肝的舒肝宁滴丸及其制备方法 | |
CN1720948A (zh) | 红茴香滴丸及其制备方法 | |
CN103520186B (zh) | 一种注射用脂溶性维生素的药物组合物及其制备方法 | |
CN102335129B (zh) | 一种供注射用依达拉奉药物组合物及其制备方法 | |
CN106176626B (zh) | L-丙氨酸-(14-冬凌草甲素)酯胃肠外用药物组合物 | |
CN1301100C (zh) | 胆木滴丸及其制备方法 | |
CN1943585A (zh) | 灯盏花素前脂质体粉末制剂及其制备方法 | |
BE1021320B1 (fr) | Composition pharmaceutique prete a l'emploi | |
CN1307981C (zh) | 一种具有止血作用的血宁滴丸及其制备方法 | |
CN109925283B (zh) | 一种替莫唑胺药物组合物及其制备方法 | |
CN1615899A (zh) | 葛根素口服制剂 | |
CN1247257C (zh) | 一种稳定的重组人红细胞生成素制剂 | |
CN1454596A (zh) | 一种银杏叶提取物与双嘧达莫复方药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090206 Address after: East Gate 2, building 1, building 301, four street, Beijing, Haidian District Patentee after: Zhang Yong Address before: East Gate 2, building 1, four street, 303 East Road, Beijing, Haidian District Patentee before: BEIJING JINGWEI XINKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO.,LTD. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHANG YONG Free format text: FORMER OWNER: BEIJING JINGWEIXINKANG MEDICINE SCIENCE DEVELOPMENT CO., LTD. Effective date: 20090206 |
|
ASS | Succession or assignment of patent right |
Owner name: TIBET ZHONGWEI XINKANG PHARMACEUTICAL TECHNOLOGY D Free format text: FORMER OWNER: ZHANG YONG Effective date: 20140807 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100085 HAIDIAN, BEIJING TO: 850000 LHASA, TIBET AUTONOMOUS REGION |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140807 Address after: 850000, Tibet autonomous region Lhasa economic and Technological Development Zone A District Tibet West Cold Chain Logistics Co., Ltd. layer 103 room Patentee after: Tibet Zhong Li Xin Kang medical science and Technology Development Co.,Ltd. Address before: 100085 No. 1, building 2, east gate, No. four, 301 street, Beijing, Haidian District Patentee before: Zhang Yong |
|
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 851400 Tibet autonomous region Lhasa economic and Technological Development Zone Incubator Park 1, workshop two, contraction joints to the south room 201-1 Patentee after: TIBET WEIXINKANG MEDICINE CO.,LTD. Address before: 850000, Tibet autonomous region Lhasa economic and Technological Development Zone A District Tibet West Cold Chain Logistics Co., Ltd. layer 103 room Patentee before: Tibet Zhong Li Xin Kang medical science and Technology Development Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20071107 |